Education
About Us
Working with TipRanks
Follow Us
Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
WHWK Stock Chart & Stats
$2.75
--
Market closed
$2.75
--
Day’s Range― - ―
52-Week Range$1.39 - $3.77
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.35M
Market Cap
$121.12M
Enterprise Value-$48.01M
Total Cash (Recent Filing)$177.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)20.3
Beta0.78
Next Earnings
Mar 12, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding47,128,360
10 Day Avg. Volume9,835,549
30 Day Avg. Volume3,352,856
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.63
Price to Sales (P/S)3.29
P/FCF Ratio-1.40
Enterprise Value/Market Cap-0.40
Enterprise Value/Revenue-2.22
Enterprise Value/Gross Profit9.41
Enterprise Value/Ebitda0.50
Forecast
1Y Price Target
$7.00Price Target Upside154.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy PotentialAnalyst notes management believes HWK-007 could raise objective response rates by roughly twenty percentage points into the forty to fifty percent range, implying meaningful efficacy upside versus current comparators.
In‑licensed Technology And Platform StrengthAnalyst highlights in‑licensing of three ADC assets with improved linker stability and pharmacokinetics as a way to address delivery and durability issues that have limited first‑generation agents.
Mechanism Of Action InnovationAnalyst points out that a biparatopic design and membrane‑targeting constructs can enhance binding specificity and tumor delivery, potentially increasing the therapeutic index over standard ADC formats.
Bears Say
Commercial Adoption And Development RiskAnalyst cautions that disappointing market uptake or failure to expand indications for related therapies underscores commercialization and regulatory risks that could weigh on sentiment.
Earnings PerformanceAnalyst flags a reported net loss per share that was wider than prior estimates, raising concerns about near‑term profitability expectations.
Operating Expense And Cash BurnAnalyst notes research and development plus general and administrative spending exceeded forecasts, which increases cash burn and heightens funding risk before key development milestones.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.39 and its highest was $3.77 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $121.12M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 57 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of $0.067 by -$0.327.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 47,128,360 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.26 in its last earnings report, missing expectations of $0.067. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.79%
12-Months-Change
Fundamentals
Return on Equity
-13.82%
Trailing 12-Months
Asset Growth
77.94%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
WHWK Stock 12 Month Forecast
Average Price Target
$7.00
▲(154.55% Upside)
Technical Analysis
Ownership Overview
26.29% Insiders
3.57% Mutual Funds
54.89% Other Institutional Investors
12.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---